VivoSeq
Oncology

Locally Advanced/metastatic Solid Tumors

1

Pipeline Programs↗

10

Active Trials↗

5

Companies Involved↗

Locally Advanced/Metastatic Solid Tumors is an early-stage landscape with 1 program across 5 companies. The most active players are Crescent Biopharma, Inc., Jiangsu Simcere Pharmaceutical Co., Ltd., Bliss Biopharmaceutical (Hangzhou) Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Crescent Biopharma, Inc.

1 program

PreclinicalJiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

0 programs

PreclinicalB

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

0 programs

PreclinicalP

Proviva Therapeutics, Inc.

0 programs

PreclinicalC

Changchun Intellicrown Pharmaceutical Co. LTD

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

CR-001

Crescent Biopharma, Inc.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Recruiting10 · 77%
Unknown status3 · 23%

Clinical Trials

Trial Activity

13 trials

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Recruiting·BBliss Biopharmaceutical (Hangzhou) Co., Ltd·Phase 1·NCT05217693·288 enrolled
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Recruiting·BBliss Biopharmaceutical (Hangzhou) Co., Ltd·Phase 1·NCT06241898·300 enrolled
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Recruiting·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT07265921·232 enrolled
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
Recruiting·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT07050459·220 enrolled
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Recruiting·HHefei TG ImmunoPharma Co., Ltd.·Phase 1·NCT07376707·194 enrolled
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Recruiting·IInSilico Medicine Hong Kong Limited·Phase 1·NCT06414460·80 enrolled
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Recruiting·PProviva Therapeutics, Inc.·Phase 1·NCT06190886·26 enrolled
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Recruiting·HHefei TG ImmunoPharma Co., Ltd.·Phase 1·NCT06374173·123 enrolled
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Recruiting·—·Phase 1/2·NCT05699811·40 enrolled
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting·CCrescent Biopharma, Inc.·Preclinical·NCT07335497·290 enrolled
An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
Unknown status·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT04671849·243 enrolled
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
Unknown status·BBJ Bioscience, Inc.·Phase 1·NCT04294576·92 enrolled
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
Unknown status·CChangchun Intellicrown Pharmaceutical Co. LTD·Phase 1·NCT04126590·39 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)